NIPER Mohali–Novartis Agreement to Boost Pharma Research

The National Institute of Pharmaceutical Education and Research (NIPER), Mohali signed a grant agreement with Novartis Healthcare Private Limited in New Delhi to promote research and innovation in the pharmaceutical sector.

The collaboration focuses on strengthening industry–academia linkages and supporting advanced research through the “Development Pioneer Grant” initiative.

The agreement aligns with the government’s vision of enhancing innovation capacity and improving healthcare outcomes in India.

NIPER:

Premier institute under the Ministry of Chemicals & Fertilizers

Total 7 NIPER institutes in India (Mohali, Hyderabad, Ahmedabad, Guwahati, Kolkata, Raebareli, Hajipur)

Novartis:

Switzerland-based global pharmaceutical company (headquartered in Basel)

Focus areas of modern pharma R&D: oncology, gene therapy, immunology

Novartis manufactures the drugs clozapine (Clozaril), diclofenac (Voltaren; sold to GlaxoSmithKline in 2015 deal), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate (Gleevec/Glivec), cyclosporine (Neoral/Sandimmune), letrozole (Femara), methylphenidate (Ritalin; produced by Sandoz since 2023), terbinafine (Lamisil), deferasirox (Exjade), and others.